Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource utilization while severely compromising patient quality of life through persistent physical symptoms, psychological distress, and substantial social disruptions.

EP: 1.The Role of Testing for C Difficile in Clinical Practice

EP: 2.Utilizing Antibiotics in Treatment of C Difficile

EP: 3.Examining FMT for Patients With Recurrent C Difficile infections

EP: 4.Exploring Rebyota for Recurrent C Difficile Infections

EP: 5.Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections

EP: 6.Vowst as a Potential Option for Patients With Recurrent C Difficile Infections

EP: 7.Management of Recurrent C Difficile Infections in the Future

EP: 8.Key Background Information on Recurrent C. Difficile Infections

EP: 9.Importance of Early Detection of Recurrent C Difficile Infections

Now Viewing

EP: 10.Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life

Video content above is prompted by the following:

• How does recurrent C difficile infection impact health care resources utilization and other medical costs?
• What are the ways in which recurrent C difficile infection can adversely impact a patient’s quality of life?
  

Related Videos

Related Content

Advertisement

January 12th 2025

Early Onset Active IBD Linked to Higher Rates of Psychiatric Disorders, Medication Use

Brooke McCormick

Early onset active inflammatory bowel disease (IBD) is associated with significantly higher rates of psychiatric disorders and increased use of psychotropic medications.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 10th 2025

Researchers Identify Potential Novel Indicator of Dysphagia in MG

AJMC Contributor

Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 9th 2025

Subcutaneous Isatuximab Meets Primary End Points in Phase 3 Study for MM

Mary Caffrey

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

January 9th 2025

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

AJMC Contributor

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

Related Content

Advertisement

January 12th 2025

Early Onset Active IBD Linked to Higher Rates of Psychiatric Disorders, Medication Use

Brooke McCormick

Early onset active inflammatory bowel disease (IBD) is associated with significantly higher rates of psychiatric disorders and increased use of psychotropic medications.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 10th 2025

Researchers Identify Potential Novel Indicator of Dysphagia in MG

AJMC Contributor

Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 9th 2025

Subcutaneous Isatuximab Meets Primary End Points in Phase 3 Study for MM

Mary Caffrey

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

January 9th 2025

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

AJMC Contributor

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).